The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0727 GMT - Klinique Medical Clinic's 2026 revenue guidance is raised, but appears already priced in by the market, CGS International's Kasem Prunratanamala says in a research report. The medical aesthetic clinic operator raised its 2026 revenue target to 4.50 billion baht from THB4.15 billion, citing strong cash sales growth in July, the analyst notes. However, the brokerage leaves its 2026-2028 earnings forecasts unchanged, pending greater clarity on growth sustainability amid intensifying competition and geopolitical headwinds. While the company's operating momentum remains healthy, thanks to drivers including resilient same-store-sale growth, its recent share price strength already captures much of this positive news. The brokerage maintains the stock's hold rating and target price of THB28.00. Shares are 1.75% higher at THB29.00.(ronnie.harui@wsj.com)

0721 GMT - European indexes are mixed in quiet early trade. Healthcare and consumer-facing stocks struggle, though AI-related stocks gain as the release of OpenAI's latest model boosts sentiment. The Stoxx 600 loses 0.15%. London's FTSE 100 slips 0.2% as miners fall, while drinks group Diageo falls 1.75%. The German Dax is flat. Chip maker Infineon jumps 2.6%, but pharmaceutical technology group Qiagen loses 2%. In Paris, the CAC 40 also trades flat, as gains for AI-related stocks counter further falls for luxuries. LVMH loses 0.9%. Italy's FTSE MIB adds 0.4%, while the Spanish IBEX 35 trades flat. The semiconductor-heavy AEX is flat. ASML gains 1.7%, but sliding software stocks weigh on the index. (josephmichael.stonor@wsj.com)

0703 GMT - An experimental Novartis medicine missed the target in a late-stage clinical trial, but the hit to the Swiss drugmaker's share price could be mitigated by investors' skepticism about the study, analysts at Citi say in a research note. The drug, pelacarsen, reduced the levels of a fatty particle in the blood known as Lp(a), but this didn't translate to clinical outcomes, Citi says. "We think market expectations of a positive trial were already cautious, with question marks around the magnitude of benefit and difficulty in commercialization even if the study had met the endpoint, which we think could limit the impact of the trial failure on the share price," the analysts say. (adria.calatayud@wsj.com)

0602 GMT - News that U.S. regulators approved AstraZeneca's new breast cancer drug Etcamah represents a minor positive for the U.K. pharmaceutical company, J.P. Morgan analysts say in a research note. The drug was approved for use in combination with medicines like Pfizer's Ibrance, Eli Lilly's Verzenio and Novartis's Kisqali to treat a type of breast cancer upon detection of a specific mutation. The authorization opens up a $1 billion sales opportunity for Etcamah, which reduces risk for one third of the consensus peak-sales estimate of $3 billion for the product, according to JPM. That said, the initial rollout of Etcamah could be slow due to the need to establish a new treatment paradigm of regular circulating tumor DNA testing to detect the mutation and a warning for arrhythmia risk, the analysts add. (adria.calatayud@wsj.com)

0543 GMT - Novartis shares are likely to take a hit from news that a cholesterol drug candidate failed to reduce the risk of severe cardiovascular events like heart attacks and strokes in a late-stage trial, J.P. Morgan analysts say in a research note. Consensus estimates for Novartis included $1 billion in 2030 sales from the drug, called pelacarsen, the analysts say. Shares in the Swiss drugmaker are likely to be off 2% to 3% on Monday as a result, they add. Upcoming trial results for del-desiran, an experimental treatment for genetic neuromuscular disorder myotonic dystrophy type 1, are likely to be positive and could allow Novartis to more than erase stock weakness caused by the pelacarsen results, according to JPM. (adria.calatayud@wsj.com)

0333 GMT - Shionogi's earnings are likely to be driven by HIV royalties, Jefferies analysts say in a note. Given that its joint-venture partner GSK has raised its HIV sales guidance, the U.S. bank expects the trend of strong HIV royalties to continue throughout the fiscal year. Over the medium- to long-term, Jefferies sees limited competitive threat and views the Shionogi-GSK HIV portfolio as solid. Jefferies also expects improving gross-profit margin for amyotrophic lateral sclerosis drug Radicava and lower marketing expenses for Covid-19 drug Xocova to contribute to profit. The bank maintains its buy rating and target price of 3,800 yen. Shares are up 1.6% at Y2,955.50. (kosaku.narioka@wsj.com; @kosakunarioka)

0118 GMT - The legal proceedings between Fortis and Daiichi Sankyo aren't expected to have material impact on IHH's associate Fortis's operations, CIMB Securities analyst Chun Sung Oong says in a note. IHH's 31.1% stake in Fortis was acquired through a fresh 40 billion rupee capital injection, with no money paid directly to the former Fortis promoters, the Singh brothers. The acquisition is therefore seen as having been conducted at arm's length, with no evidence of direct dealings with the former promoters, he says. IHH also reaffirmed its intention to gradually raise its stake in Fortis to 51% over the next four years, which is expected to have minimal impact on its target price. CIMB maintains a buy rating on IHH and its target price at 10.30 ringgit. Shares are at 7.96 ringgit.